Global Blau Syndrome Market - Industry Trends and Forecast to 2027
- DBMR959
- Pages: 438
- July 2020
- Total Views:1124
- Region : Global
- Data Bridge Market Research
- Market Research Report
Details
Global Blau syndrome market is projected to register a healthy CAGR of 11.9% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
Global Blau Syndrome Market, By Type (Treatment and Diagnosis), Therapeutic Areas (Skin Rash, Inflammation), Route of Administration (Oral, Parenteral, Topical, Others), End User (Hospitals, Diagnostic Centers, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey and Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific, Brazil, Argentina and Rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Egypt and Rest of Middle East and Africa)-Industry Trends & Forecast to 2027
Some of the major factors contributing to the growth of global Blau syndrome market are:
Emergence of drugs used to treat symptoms associated with Blau syndrome
Advancement in health care industry
Market Players:
The key market players for global Blau syndrome market are listed below:
Novartis AG
Pfizer Inc.
AbbVie Inc.
Amgen Inc.
Janssen Pharmaceuticals, Inc.(A Subsidiary of Johnson & Johnson Services Inc.)
Mylan N.V.
Hikma Pharmaceuticals PLC
Teva Pharmaceutical U.S.A Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.)
Fulgent Genetics Inc.
Invitae Corporation
Swedish Orphan Biovitrum AB
Alkem Labs
Accord Healthcare
F. Hoffmann-La Roche Ltd
Zydus Pharmaceuticals (USA) Inc. (a subsidiary of Zydus cadila)
Amneal Pharmaceuticals LLC
Salix Pharmaceuticals (a subsidiary of Bausch Health Companies Inc.)
Centogene AG
Oncodesign
Table Of Content
Scope
TABLE OF CONTENTS
1 INTRODUCTION 58
1.1 OBJECTIVES OF THE STUDY 58
1.2 MARKET DEFINITION 58
1.3 OVERVIEW OF GLOBAL BLAU SYNDROME MARKET 58
1.4 LIMITATIONS 60
1.5 MARKETS COVERED 60
2 MARKET SEGMENTATION 64
2.1 MARKETS COVERED 64
2.2 GEOGRAPHICAL SCOPE 65
2.3 YEARS CONSIDERED FOR THE STUDY 66
2.4 CURRENCY AND PRICING 66
2.5 DBMR TRIPOD DATA VALIDATION MODEL 67
2.6 MULTIVARIATE MODELLING 70
2.7 THERAPEUTIC AREAS OF BLAU SYNDROME LIFELINE CURVE 70
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 71
2.9 DBMR MARKET POSITION GRID 72
2.10 VENDOR SHARE ANALYSIS 73
2.11 SECONDARY SOURCES 74
2.12 ASSUMPTIONS 74
3 EXECUTIVE SUMMARY 75
4 GLOBAL BLAU SYNDROME MARKET: REGULATIONS 80
5 MARKET OVERVIEW 82
5.1 DRIVERS 84
5.1.1 HIGH ADOPTION OF BIOLOGICAL THERAPIES 84
5.1.2 EMERGENCE OF DRUGS USED TO TREAT SYMPTOMS ASSOCIATED WITH BLAU SYNDROME 84
5.1.3 HIGH DEMAND OF DISEASE SPECIFIC TREATMENT 85
5.1.4 ADVANCEMENTS IN HEALTH CARE INDUSTRY 85
5.1.5 AVAILABILITY OF OFF LABEL DRUGS 86
5.2 RESTRAINTS 87
5.2.1 UNAVAILABILITY AND UNAFFORDABILITY OF EFFECTIVE TREATMENT 87
5.2.2 POOR DIAGNOSIS RATE IN SOME DEVELOPING COUNTRIES 87
5.2.3 LARGE NUMBER OF SIDE EFFECTS OF AVAILABLE DRUGS 87
5.3 OPPORTUNITIES 88
5.3.1 RISING DISPOSABLE INCOME 88
5.3.2 RISING STRATEGIC INITIATIVES BY PHARMACEUTICAL COMPANIES 88
5.3.3 EMERGING MARKETS 89
5.3.4 INCREASING RESEARCH AND DEVELOPMENT 89
5.4 CHALLENGES 90
5.4.1 LACK OF APPROVED DRUGS 90
5.4.2 HIGH COST ASSOCIATED WITH SYNDROME DIAGONSIS 90
5.4.3 LACK OF SKILLED RESOURCE FOR PERFORMING GENETIC TESTS 90
6 IMPACT OF COVID-19 PANDEMIC ON THE GLOBAL BLAU SYNDROME MARKET 91
6.1 PRICE IMPACT 91
6.2 IMPACT ON DEMAND 91
6.3 IMPACT ON SUPPLY CHAIN 92
6.4 STRATEGIC DECISIONS FOR MANUFACTURERS 92
6.5 CONCLUSION 93
7 GLOBAL BLAU SYNDROME MARKET, BY TYPE 94
7.1 OVERVIEW 95
7.2 TREATMENT 98
7.2.1 CORTICOSTEROIDS 99
7.2.1.1 PREDNISOLONE 99
7.2.1.2 COMBINATION CORTICOSTEROIDS 99
7.2.1.3 NAPROXEN 99
7.2.1.4 OTHERS 99
7.2.2 IMMUNOSUPPRESSANTS 99
7.2.2.1 METHOTREXATE 100
7.2.2.2 MYCOPHENOLATE MOFETIL 100
7.2.2.3 AZATHIOPRINE 100
7.2.2.4 OTHERS 100
7.2.3 TNF-? INHIBITORS 100
7.2.3.1 INFLIXIMAB 101
7.2.3.2 ADALIMUMAB 101
7.2.3.3 ETANERCEPT 101
7.2.3.4 OTHERS 101
7.2.4 OPTHALMIC MEDICATION 101
7.2.4.1 PREDNISOLONE ACETATE 101
7.2.4.2 TROPICAMIDE 101
7.2.4.3 OTHERS 101
7.2.5 INTERLEUKIN RECEPTOR 102
7.2.5.1 ANAKINRA 102
7.2.5.2 CANAKINUMAB 102
7.2.5.3 OTHERS 102
7.2.6 OTHERS 102
7.3 DIAGNOSIS 102
7.3.1 SCREENING 103
7.3.1.1 LAB TEST 104
7.3.1.1.1 BLOOD TEST 104
7.3.1.1.2 SALIVA TEST 104
7.3.1.1.3 OTHERS 104
7.3.1.2 IMAGING TEST 104
7.3.1.2.1 CT SCANS 104
7.3.1.2.2 ULTRASOUNDS 105
7.3.1.2.3 OTHERS 105
7.3.2 CONFIRMATORY TEST 105
7.3.2.1 SKIN BIOPSY 105
7.3.2.2 GENETIC TEST 105
7.3.2.3 OTHERS 105
8 GLOBAL BLAU SYNDROME MARKET, BY THERAPEUTIC AREAS 106
8.1 OVERVIEW 107
8.2 SKIN RASH 110
8.3 INFLAMMATION 110
8.3.1 GRANULOMATOUS DERMATITIS 112
8.3.2 SYNOVITIS 112
8.3.3 UVEITIS 112
8.3.4 GRANULOMATOUS ARTHRITIS 112
8.3.5 CHRONIC ARTHRITIS 112
8.3.6 OTHERS 112
9 GLOBAL BLAU SYNDROME MARKET, BY ROUTE OF ADMINISTRATION 113
9.1 OVERVIEW 114
9.2 ORAL 117
9.2.1 TABLET 118
9.2.2 CAPSULE 118
9.2.3 OTHERS 118
9.3 PARENTERAL 118
9.3.1 INTRAVENOUS 119
9.3.2 SUBCUTANEOUS 119
9.3.3 OTHERS 119
9.4 TOPICAL 119
9.4.1 OINTMENT 120
9.4.2 SOLUTION 120
9.4.3 OTHERS 120
9.5 OTHERS 120
10 GLOBAL BLAU SYNDROME MARKET, BY END USER 122
10.1 OVERVIEW 123
10.2 HOSPITALS 125
10.3 DIAGNOSTICS CENTERS 126
10.4 CLINICS 127
10.5 HOME HEALTHCARE 127
10.6 OTHERS 128
11 GLOBAL BLAU SYNDROME MARKET, BY DISTRIBUTION CHANNEL 129
11.1 OVERVIEW 130
11.2 HOSPITAL PHARMACY 132
11.3 RETAIL PHARMACY 133
11.4 ONLINE PHARMACY 134
11.5 DIRECT TENDER 135
11.6 OTHERS 136
12 GLOBAL BLAU SYNDROME MARKET, BY GEOGRAPHY 137
12.1 OVERVIEW 138
12.2 NORTH AMERICA 143
12.2.1 U.S. 152
12.2.2 CANADA 157
12.2.3 MEXICO 162
12.3 EUROPE 167
12.3.1 GERMANY 176
12.3.2 FRANCE 181
12.3.3 U.K. 186
12.3.4 ITALY 191
12.3.5 NETHERLANDS 196
12.3.6 SPAIN 202
12.3.7 RUSSIA 207
12.3.8 SWITZERLAND 212
12.3.9 TURKEY 218
12.3.10 AUSTRIA 223
12.3.11 NORWAY 228
12.3.12 HUNGARY 233
12.3.13 LITHUANIA 238
12.3.14 IRELAND 243
12.3.15 POLAND 248
12.3.16 REST OF EUROPE 253
12.4 ASIA PACIFIC 254
12.4.1 JAPAN 263
12.4.2 CHINA 268
12.4.3 AUSTRAILA 273
12.4.4 SOUTH KOREA 279
12.4.5 INDIA 285
12.4.6 SINGAPORE 290
12.4.7 MALAYSIA 296
12.4.8 THAILAND 301
12.4.9 INDONESIA 306
12.4.10 PHILIPPINES 312
12.4.11 VIETNAM 318
12.4.12 REST OF ASIA-PACIFIC 323
12.5 SOUTH AMERICA 324
12.5.1 BRAZIL 333
12.5.2 ARGENTINA 338
12.5.3 PERU 344
12.5.4 REST OF SOUTH AMERICA 349
12.6 MIDDLE EAST & AFRICA 350
12.6.1 SAUDI ARABIA 359
12.6.2 SOUTH AFRICA 365
12.6.3 UAE 371
12.6.4 ISRAEL 376
12.6.5 KUWAIT 381
12.6.6 EGYPT 386
12.6.7 REST OF MIDDLE EAST & AFRICA 391
13 GLOBAL BLAU SYNDROME MARKET, COMPANY LANDSCAPE 392
13.1 COMPANY SHARE ANALYSIS: GLOBAL 392
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 393
13.3 COMPANY SHARE ANALYSIS: EUROPE 394
13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 395
14 SWOT 396
15 COMPANY PROFILES 397
15.1 NOVARTIS AG 397
15.1.1 COMPANY SNAPSHOT 397
15.1.2 REVENUE ANALYSIS 397
15.1.3 COMPANY SHARE ANALYSIS 398
15.1.4 PRODUCT PORTFOLIO 398
15.1.5 RECENT DEVELOPMENTS 398
15.2 AMGEN INC. 399
15.2.1 COMPANY SNAPSHOT 399
15.2.2 REVENUE ANALYSIS 399
15.2.3 COMPANY SHARE ANALYSIS 400
15.2.4 PRODUCT PORTFOLIO 400
15.2.5 RECENT DEVELOPMENTS 400
15.3 PFIZER INC. 401
15.3.1 COMPANY SNAPSHOT 401
15.3.2 REVENUE ANALYSIS 401
15.3.3 COMPANY SHARE ANALYSIS 402
15.3.4 PRODUCT PORTFOLIO 402
15.3.5 RECENT DEVELOPMENTS 402
15.4 JANSSEN PHARMACEUTICALS, INC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 403
15.4.1 COMPANY SNAPSHOT 403
15.4.2 REVENUE ANALYSIS 403
15.4.3 COMPANY SHARE ANALYIS 404
15.4.4 PRODUCT PORTFOLIO 404
15.4.5 RECENT DEVELOPMENT 404
15.5 ABBVIE INC. 405
15.5.1 COMPANY SNAPSHOT 405
15.5.2 REVENUE ANALYSIS 405
15.5.3 COMPANY SHARE ANALYSIS 406
15.5.4 PRODUCT PORTFOLIO 406
15.5.5 RECENT DEVELOPMENTS 406
15.6 ACCORD HEALTHCARE 408
15.6.1 COMPANY SNAPSHOT 408
15.6.2 PRODUCT PORTFOLIO 408
15.6.3 RECENT DEVELOPMENTS 408
15.7 ALKEM LABS 409
15.7.1 COMPANY SNAPSHOT 409
15.7.2 REVENUE ANALYSIS 409
15.7.3 PRODUCT PORTFOLIO 410
15.7.4 RECENT DEVELOPMENT 410
15.8 AMNEAL PHARMACEUTICALS LLC 411
15.8.1 COMPANY SNAPSHOT 411
15.8.2 REVENUE ANALYSIS 411
15.8.3 PRODUCT PORTFOLIO 411
15.8.4 RECENT DEVELOPMENTS 412
15.9 CENTOGENE N.V. 413
15.9.1 COMPANY SNAPSHOT 413
15.9.2 REVENUE ANALYSIS 413
15.9.3 PRODUCT PORTFOLIO 413
15.9.4 RECENT DEVELOPMENTS 414
15.10 F. HOFFMANN-LA ROCHE LTD 415
15.10.1 COMPANY SNAPSHOT 415
15.10.2 REVENUE ANALYSIS 415
15.10.3 PRODUCT PORTFOLIO 416
15.10.4 RECENT DEVELOPMENT 416
15.11 FULGENT GENETICS 417
15.11.1 COMPANY SNAPSHOT 417
15.11.2 REVENUE ANALYSIS 417
15.11.3 PRODUCT PORTFOLIO 417
15.11.4 RECENT DEVELOPMENT 418
15.12 HIKMA PHARMACEUTICALS PLC 419
15.12.1 COMPANY SNAPSHOT 419
15.12.2 REVENUE ANALYSIS 419
15.12.3 PRODUCT PORTFOLIO 420
15.12.4 RECENT DEVELOPMENTS 420
15.13 INVITAE CORPORATION 421
15.13.1 COMPANY SNAPSHOT 421
15.13.2 REVENUE ANALYSIS 421
15.13.3 PRODUCT PORTFOLIO 422
15.13.4 RECENT DEVELOPMENTS 422
15.14 MYLAN N.V. 423
15.14.1 COMPANY SNAPSHOT 423
15.14.2 REVENUE ANALYSIS 423
15.14.3 PRODUCT PORTFOLIO 424
15.14.4 RECENT DEVELOPMENTS 424
15.15 ONCODESIGN 425
15.15.1 COMPANY SNAPSHOT 425
15.15.2 REVENUE ANALYSIS 425
15.15.3 PRODUCT PORTFOLIO 425
15.15.4 RECENT DEVELOPMENT 426
15.16 SALIX PHARMACEUTICALS (A SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.) 427
15.16.1 COMPANY SNAPSHOT 427
15.16.2 REVENUE ANALYSIS 427
15.16.3 PRODUCT PORTFOLIO 428
15.16.4 RECENT DEVELOPMENT 428
15.17 SWEDISH ORPHAN BIOVITRUM AB (PUBL) 429
15.17.1 COMPANY SNAPSHOT 429
15.17.2 REVENUE ANALYSIS 429
15.17.3 PRODUCT PORTFOLIO 429
15.17.4 RECENT DEVELOPMENTS 430
15.18 TEVA PHARMACEUTICAL USA INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.) 431
15.18.1 COMPANY SNAPSHOT 431
15.18.2 REVENUE ANALYSIS 431
15.18.3 PRODUCT PORTFOLIO 432
15.18.4 RECENT DEVELOPMENTS 432
15.19 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA) 433
15.19.1 COMPANY SNAPSHOT 433
15.19.2 REVENUE ANALYSIS 433
15.19.3 PRODUCT PORTFOLIO 433
15.19.4 RECENT DEVELOPMENTS 434
16 QUESTIONNAIRE 435
17 RELATED REPORTS 438
List Of Figure
LIST OF FIGURES
FIGURE 1 GLOBAL BLAU SYNDROME MARKET: SEGMENTATION 64
FIGURE 2 GLOBAL BLAU SYNDROME MARKET : DATA TRIANGULATION 67
FIGURE 3 GLOBAL BLAU SYNDROME MARKET: DROC ANALYSIS 68
FIGURE 4 GLOBAL BLAU SYNDROME MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 69
FIGURE 5 GLOBAL BLAU SYNDROME MARKET: COMPANY RESEARCH ANALYSIS 69
FIGURE 6 GLOBAL BLAU SYNDROME MARKET: MULTIVARIATE MODELLING 70
FIGURE 7 GLOBAL BLAU SYNDROME MARKET: INTERVIEW DEMOGRAPHICS 71
FIGURE 8 GLOBAL BLAU SYNDROME MARKET: DBMR MARKET POSITION GRID 72
FIGURE 9 GLOBAL BLAU SYNDROME MARKET: VENDOR SHARE ANALYSIS 73
FIGURE 10 GLOBAL BLAU SYNDROME MARKET: SEGMENTATION 76
FIGURE 11 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL BLAU SYNDROME MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 77
FIGURE 12 HIGH ADOPTION OF BIOLOGICAL THERAPIES AND HIGH DEMAND OF DISEASE SPECIFIC TREATMENT IS DRIVING THE GLOBAL BLAU SYNDROME MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 78
FIGURE 13 TREATMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL BLAU SYNDROME MARKET IN 2020 & 2027 78
FIGURE 14 NORTH AMERICA IS THE FASTEST GROWING MARKET IN GLOBAL BLAU SYNDROME MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 79
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES OF GLOBAL BLAU SYNDROME MARKET 83
FIGURE 16 GLOBAL BLAU SYNDROME MARKET: BY TYPE, 2019 95
FIGURE 17 GLOBAL BLAU SYNDROME MARKET: BY TYPE, 2019-2027 (USD THOUSAND) 96
FIGURE 18 GLOBAL BLAU SYNDROME MARKET: BY TYPE, CAGR (2020-2027) 96
FIGURE 19 GLOBAL BLAU SYNDROME MARKET: BY TYPE, LIFELINE CURVE 97
FIGURE 20 GLOBAL BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, 2019 107
FIGURE 21 GLOBAL BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, 2019-2027 (USD THOUSAND) 108
FIGURE 22 GLOBAL BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, CAGR (2020-2027) 108
FIGURE 23 GLOBAL BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, LIFELINE CURVE 109
FIGURE 24 GLOBAL TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, 2019 114
FIGURE 25 GLOBAL TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD THOUSAND) 115
FIGURE 26 GLOBAL TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027) 115
FIGURE 27 GLOBAL TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 116
FIGURE 28 GLOBAL BLAU SYNDROME MARKET: BY END USER, 2019 123
FIGURE 29 GLOBAL BLAU SYNDROME MARKET: BY END USER, 2019-2027 (USD THOUSAND) 124
FIGURE 30 GLOBAL BLAU SYNDROME MARKET: BY END USER, CAGR (2020-2027) 124
FIGURE 31 GLOBAL BLAU SYNDROME MARKET: BY END USER, LIFELINE CURVE 125
FIGURE 32 GLOBAL BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2019 130
FIGURE 33 GLOBAL BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSAND) 131
FIGURE 34 GLOBAL BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027) 131
FIGURE 35 GLOBAL BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 132
FIGURE 36 GLOBAL BLAU SYNDROME MARKET: SNAPSHOT (2019) 139
FIGURE 37 GLOBAL BLAU SYNDROME MARKET: BY REGION (2019) 140
FIGURE 38 GLOBAL BLAU SYNDROME MARKET: BY REGION (2020 & 2027) 140
FIGURE 39 GLOBAL BLAU SYNDROME MARKET: BY REGION (2019 & 2027) 141
FIGURE 40 GLOBAL BLAU SYNDROME MARKET: BY TYPE (2020-2027) 141
FIGURE 41 NORTH AMERICA BLAU SYNDROME MARKET: SNAPSHOT (2019) 143
FIGURE 42 NORTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2019) 144
FIGURE 43 NORTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 144
FIGURE 44 NORTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 145
FIGURE 45 NORTH AMERICA BLAU SYNDROME MARKET: BY TYPE (2020-2027) 145
FIGURE 46 EUROPE BLAU SYNDROME MARKET: SNAPSHOT (2019) 167
FIGURE 47 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2019) 168
FIGURE 48 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 168
FIGURE 49 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 169
FIGURE 50 EUROPE BLAU SYNDROME MARKET: BY TYPE (2020-2027) 169
FIGURE 51 ASIA PACIFIC BLAU SYNDROME MARKET: SNAPSHOT (2019) 254
FIGURE 52 ASIA PACIFIC BLAU SYNDROME MARKET: BY COUNTRY (2019) 255
FIGURE 53 ASIA PACIFIC BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 255
FIGURE 54 ASIA PACIFIC BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 256
FIGURE 55 ASIA PACIFIC BLAU SYNDROME MARKET: BY TYPE (2020-2027) 256
FIGURE 56 SOUTH AMERICA BLAU SYNDROME MARKET: SNAPSHOT (2019) 324
FIGURE 57 SOUTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2019) 325
FIGURE 58 SOUTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 325
FIGURE 59 SOUTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 326
FIGURE 60 SOUTH AMERICA BLAU SYNDROME MARKET: BY TYPE (2020-2027) 326
FIGURE 61 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: SNAPSHOT (2019) 350
FIGURE 62 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: BY COUNTRY (2019) 351
FIGURE 63 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 351
FIGURE 64 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 352
FIGURE 65 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: BY TYPE (2020-2027) 352
FIGURE 66 GLOBAL BLAU SYNDROME MARKET: COMPANY SHARE 2019 (%) 392
FIGURE 67 NORTH AMERICA BLAU SYNDROME MARKET: COMPANY SHARE 2019 (%) 393
FIGURE 68 EUROPE BLAU SYNDROME MARKET: COMPANY SHARE 2019 (%) 394
FIGURE 69 ASIA-PACIFIC BLAU SYNDROME MARKET: COMPANY SHARE 2019 (%) 395
Licence Rights
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Companies
Novartis AG
Pfizer Inc.
AbbVie Inc.
Amgen Inc.
Janssen Pharmaceuticals, Inc.(A Subsidiary of Johnson & Johnson Services Inc.)
Mylan N.V.
Hikma Pharmaceuticals PLC
Teva Pharmaceutical U.S.A Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.)
Fulgent Genetics Inc.
Invitae Corporation
Swedish Orphan Biovitrum AB
Alkem Labs
Accord Healthcare
F. Hoffmann-La Roche Ltd
Zydus Pharmaceuticals (USA) Inc. (a subsidiary of Zydus cadila)
Amneal Pharmaceuticals LLC
Salix Pharmaceuticals (a subsidiary of Bausch Health Companies Inc.)
Centogene AG
Oncodesign
Company Profile
Company Profile Title
Global Blau syndrome market is projected to register a healthy CAGR of 11.9% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
Global Blau Syndrome Market, By Type (Treatment and Diagnosis), Therapeutic Areas (Skin Rash, Inflammation), Route of Administration (Oral, Parenteral, Topical, Others), End User (Hospitals, Diagnostic Centers, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey and Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific, Brazil, Argentina and Rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Egypt and Rest of Middle East and Africa)-Industry Trends & Forecast to 2027
Some of the major factors contributing to the growth of global Blau syndrome market are:
Emergence of drugs used to treat symptoms associated with Blau syndrome
Advancement in health care industry
Market Players:
The key market players for global Blau syndrome market are listed below:
Novartis AG
Pfizer Inc.
AbbVie Inc.
Amgen Inc.
Janssen Pharmaceuticals, Inc.(A Subsidiary of Johnson & Johnson Services Inc.)
Mylan N.V.
Hikma Pharmaceuticals PLC
Teva Pharmaceutical U.S.A Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.)
Fulgent Genetics Inc.
Invitae Corporation
Swedish Orphan Biovitrum AB
Alkem Labs
Accord Healthcare
F. Hoffmann-La Roche Ltd
Zydus Pharmaceuticals (USA) Inc. (a subsidiary of Zydus cadila)
Amneal Pharmaceuticals LLC
Salix Pharmaceuticals (a subsidiary of Bausch Health Companies Inc.)
Centogene AG
Oncodesign
Scope
TABLE OF CONTENTS
1 INTRODUCTION 58
1.1 OBJECTIVES OF THE STUDY 58
1.2 MARKET DEFINITION 58
1.3 OVERVIEW OF GLOBAL BLAU SYNDROME MARKET 58
1.4 LIMITATIONS 60
1.5 MARKETS COVERED 60
2 MARKET SEGMENTATION 64
2.1 MARKETS COVERED 64
2.2 GEOGRAPHICAL SCOPE 65
2.3 YEARS CONSIDERED FOR THE STUDY 66
2.4 CURRENCY AND PRICING 66
2.5 DBMR TRIPOD DATA VALIDATION MODEL 67
2.6 MULTIVARIATE MODELLING 70
2.7 THERAPEUTIC AREAS OF BLAU SYNDROME LIFELINE CURVE 70
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 71
2.9 DBMR MARKET POSITION GRID 72
2.10 VENDOR SHARE ANALYSIS 73
2.11 SECONDARY SOURCES 74
2.12 ASSUMPTIONS 74
3 EXECUTIVE SUMMARY 75
4 GLOBAL BLAU SYNDROME MARKET: REGULATIONS 80
5 MARKET OVERVIEW 82
5.1 DRIVERS 84
5.1.1 HIGH ADOPTION OF BIOLOGICAL THERAPIES 84
5.1.2 EMERGENCE OF DRUGS USED TO TREAT SYMPTOMS ASSOCIATED WITH BLAU SYNDROME 84
5.1.3 HIGH DEMAND OF DISEASE SPECIFIC TREATMENT 85
5.1.4 ADVANCEMENTS IN HEALTH CARE INDUSTRY 85
5.1.5 AVAILABILITY OF OFF LABEL DRUGS 86
5.2 RESTRAINTS 87
5.2.1 UNAVAILABILITY AND UNAFFORDABILITY OF EFFECTIVE TREATMENT 87
5.2.2 POOR DIAGNOSIS RATE IN SOME DEVELOPING COUNTRIES 87
5.2.3 LARGE NUMBER OF SIDE EFFECTS OF AVAILABLE DRUGS 87
5.3 OPPORTUNITIES 88
5.3.1 RISING DISPOSABLE INCOME 88
5.3.2 RISING STRATEGIC INITIATIVES BY PHARMACEUTICAL COMPANIES 88
5.3.3 EMERGING MARKETS 89
5.3.4 INCREASING RESEARCH AND DEVELOPMENT 89
5.4 CHALLENGES 90
5.4.1 LACK OF APPROVED DRUGS 90
5.4.2 HIGH COST ASSOCIATED WITH SYNDROME DIAGONSIS 90
5.4.3 LACK OF SKILLED RESOURCE FOR PERFORMING GENETIC TESTS 90
6 IMPACT OF COVID-19 PANDEMIC ON THE GLOBAL BLAU SYNDROME MARKET 91
6.1 PRICE IMPACT 91
6.2 IMPACT ON DEMAND 91
6.3 IMPACT ON SUPPLY CHAIN 92
6.4 STRATEGIC DECISIONS FOR MANUFACTURERS 92
6.5 CONCLUSION 93
7 GLOBAL BLAU SYNDROME MARKET, BY TYPE 94
7.1 OVERVIEW 95
7.2 TREATMENT 98
7.2.1 CORTICOSTEROIDS 99
7.2.1.1 PREDNISOLONE 99
7.2.1.2 COMBINATION CORTICOSTEROIDS 99
7.2.1.3 NAPROXEN 99
7.2.1.4 OTHERS 99
7.2.2 IMMUNOSUPPRESSANTS 99
7.2.2.1 METHOTREXATE 100
7.2.2.2 MYCOPHENOLATE MOFETIL 100
7.2.2.3 AZATHIOPRINE 100
7.2.2.4 OTHERS 100
7.2.3 TNF-? INHIBITORS 100
7.2.3.1 INFLIXIMAB 101
7.2.3.2 ADALIMUMAB 101
7.2.3.3 ETANERCEPT 101
7.2.3.4 OTHERS 101
7.2.4 OPTHALMIC MEDICATION 101
7.2.4.1 PREDNISOLONE ACETATE 101
7.2.4.2 TROPICAMIDE 101
7.2.4.3 OTHERS 101
7.2.5 INTERLEUKIN RECEPTOR 102
7.2.5.1 ANAKINRA 102
7.2.5.2 CANAKINUMAB 102
7.2.5.3 OTHERS 102
7.2.6 OTHERS 102
7.3 DIAGNOSIS 102
7.3.1 SCREENING 103
7.3.1.1 LAB TEST 104
7.3.1.1.1 BLOOD TEST 104
7.3.1.1.2 SALIVA TEST 104
7.3.1.1.3 OTHERS 104
7.3.1.2 IMAGING TEST 104
7.3.1.2.1 CT SCANS 104
7.3.1.2.2 ULTRASOUNDS 105
7.3.1.2.3 OTHERS 105
7.3.2 CONFIRMATORY TEST 105
7.3.2.1 SKIN BIOPSY 105
7.3.2.2 GENETIC TEST 105
7.3.2.3 OTHERS 105
8 GLOBAL BLAU SYNDROME MARKET, BY THERAPEUTIC AREAS 106
8.1 OVERVIEW 107
8.2 SKIN RASH 110
8.3 INFLAMMATION 110
8.3.1 GRANULOMATOUS DERMATITIS 112
8.3.2 SYNOVITIS 112
8.3.3 UVEITIS 112
8.3.4 GRANULOMATOUS ARTHRITIS 112
8.3.5 CHRONIC ARTHRITIS 112
8.3.6 OTHERS 112
9 GLOBAL BLAU SYNDROME MARKET, BY ROUTE OF ADMINISTRATION 113
9.1 OVERVIEW 114
9.2 ORAL 117
9.2.1 TABLET 118
9.2.2 CAPSULE 118
9.2.3 OTHERS 118
9.3 PARENTERAL 118
9.3.1 INTRAVENOUS 119
9.3.2 SUBCUTANEOUS 119
9.3.3 OTHERS 119
9.4 TOPICAL 119
9.4.1 OINTMENT 120
9.4.2 SOLUTION 120
9.4.3 OTHERS 120
9.5 OTHERS 120
10 GLOBAL BLAU SYNDROME MARKET, BY END USER 122
10.1 OVERVIEW 123
10.2 HOSPITALS 125
10.3 DIAGNOSTICS CENTERS 126
10.4 CLINICS 127
10.5 HOME HEALTHCARE 127
10.6 OTHERS 128
11 GLOBAL BLAU SYNDROME MARKET, BY DISTRIBUTION CHANNEL 129
11.1 OVERVIEW 130
11.2 HOSPITAL PHARMACY 132
11.3 RETAIL PHARMACY 133
11.4 ONLINE PHARMACY 134
11.5 DIRECT TENDER 135
11.6 OTHERS 136
12 GLOBAL BLAU SYNDROME MARKET, BY GEOGRAPHY 137
12.1 OVERVIEW 138
12.2 NORTH AMERICA 143
12.2.1 U.S. 152
12.2.2 CANADA 157
12.2.3 MEXICO 162
12.3 EUROPE 167
12.3.1 GERMANY 176
12.3.2 FRANCE 181
12.3.3 U.K. 186
12.3.4 ITALY 191
12.3.5 NETHERLANDS 196
12.3.6 SPAIN 202
12.3.7 RUSSIA 207
12.3.8 SWITZERLAND 212
12.3.9 TURKEY 218
12.3.10 AUSTRIA 223
12.3.11 NORWAY 228
12.3.12 HUNGARY 233
12.3.13 LITHUANIA 238
12.3.14 IRELAND 243
12.3.15 POLAND 248
12.3.16 REST OF EUROPE 253
12.4 ASIA PACIFIC 254
12.4.1 JAPAN 263
12.4.2 CHINA 268
12.4.3 AUSTRAILA 273
12.4.4 SOUTH KOREA 279
12.4.5 INDIA 285
12.4.6 SINGAPORE 290
12.4.7 MALAYSIA 296
12.4.8 THAILAND 301
12.4.9 INDONESIA 306
12.4.10 PHILIPPINES 312
12.4.11 VIETNAM 318
12.4.12 REST OF ASIA-PACIFIC 323
12.5 SOUTH AMERICA 324
12.5.1 BRAZIL 333
12.5.2 ARGENTINA 338
12.5.3 PERU 344
12.5.4 REST OF SOUTH AMERICA 349
12.6 MIDDLE EAST & AFRICA 350
12.6.1 SAUDI ARABIA 359
12.6.2 SOUTH AFRICA 365
12.6.3 UAE 371
12.6.4 ISRAEL 376
12.6.5 KUWAIT 381
12.6.6 EGYPT 386
12.6.7 REST OF MIDDLE EAST & AFRICA 391
13 GLOBAL BLAU SYNDROME MARKET, COMPANY LANDSCAPE 392
13.1 COMPANY SHARE ANALYSIS: GLOBAL 392
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 393
13.3 COMPANY SHARE ANALYSIS: EUROPE 394
13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 395
14 SWOT 396
15 COMPANY PROFILES 397
15.1 NOVARTIS AG 397
15.1.1 COMPANY SNAPSHOT 397
15.1.2 REVENUE ANALYSIS 397
15.1.3 COMPANY SHARE ANALYSIS 398
15.1.4 PRODUCT PORTFOLIO 398
15.1.5 RECENT DEVELOPMENTS 398
15.2 AMGEN INC. 399
15.2.1 COMPANY SNAPSHOT 399
15.2.2 REVENUE ANALYSIS 399
15.2.3 COMPANY SHARE ANALYSIS 400
15.2.4 PRODUCT PORTFOLIO 400
15.2.5 RECENT DEVELOPMENTS 400
15.3 PFIZER INC. 401
15.3.1 COMPANY SNAPSHOT 401
15.3.2 REVENUE ANALYSIS 401
15.3.3 COMPANY SHARE ANALYSIS 402
15.3.4 PRODUCT PORTFOLIO 402
15.3.5 RECENT DEVELOPMENTS 402
15.4 JANSSEN PHARMACEUTICALS, INC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 403
15.4.1 COMPANY SNAPSHOT 403
15.4.2 REVENUE ANALYSIS 403
15.4.3 COMPANY SHARE ANALYIS 404
15.4.4 PRODUCT PORTFOLIO 404
15.4.5 RECENT DEVELOPMENT 404
15.5 ABBVIE INC. 405
15.5.1 COMPANY SNAPSHOT 405
15.5.2 REVENUE ANALYSIS 405
15.5.3 COMPANY SHARE ANALYSIS 406
15.5.4 PRODUCT PORTFOLIO 406
15.5.5 RECENT DEVELOPMENTS 406
15.6 ACCORD HEALTHCARE 408
15.6.1 COMPANY SNAPSHOT 408
15.6.2 PRODUCT PORTFOLIO 408
15.6.3 RECENT DEVELOPMENTS 408
15.7 ALKEM LABS 409
15.7.1 COMPANY SNAPSHOT 409
15.7.2 REVENUE ANALYSIS 409
15.7.3 PRODUCT PORTFOLIO 410
15.7.4 RECENT DEVELOPMENT 410
15.8 AMNEAL PHARMACEUTICALS LLC 411
15.8.1 COMPANY SNAPSHOT 411
15.8.2 REVENUE ANALYSIS 411
15.8.3 PRODUCT PORTFOLIO 411
15.8.4 RECENT DEVELOPMENTS 412
15.9 CENTOGENE N.V. 413
15.9.1 COMPANY SNAPSHOT 413
15.9.2 REVENUE ANALYSIS 413
15.9.3 PRODUCT PORTFOLIO 413
15.9.4 RECENT DEVELOPMENTS 414
15.10 F. HOFFMANN-LA ROCHE LTD 415
15.10.1 COMPANY SNAPSHOT 415
15.10.2 REVENUE ANALYSIS 415
15.10.3 PRODUCT PORTFOLIO 416
15.10.4 RECENT DEVELOPMENT 416
15.11 FULGENT GENETICS 417
15.11.1 COMPANY SNAPSHOT 417
15.11.2 REVENUE ANALYSIS 417
15.11.3 PRODUCT PORTFOLIO 417
15.11.4 RECENT DEVELOPMENT 418
15.12 HIKMA PHARMACEUTICALS PLC 419
15.12.1 COMPANY SNAPSHOT 419
15.12.2 REVENUE ANALYSIS 419
15.12.3 PRODUCT PORTFOLIO 420
15.12.4 RECENT DEVELOPMENTS 420
15.13 INVITAE CORPORATION 421
15.13.1 COMPANY SNAPSHOT 421
15.13.2 REVENUE ANALYSIS 421
15.13.3 PRODUCT PORTFOLIO 422
15.13.4 RECENT DEVELOPMENTS 422
15.14 MYLAN N.V. 423
15.14.1 COMPANY SNAPSHOT 423
15.14.2 REVENUE ANALYSIS 423
15.14.3 PRODUCT PORTFOLIO 424
15.14.4 RECENT DEVELOPMENTS 424
15.15 ONCODESIGN 425
15.15.1 COMPANY SNAPSHOT 425
15.15.2 REVENUE ANALYSIS 425
15.15.3 PRODUCT PORTFOLIO 425
15.15.4 RECENT DEVELOPMENT 426
15.16 SALIX PHARMACEUTICALS (A SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.) 427
15.16.1 COMPANY SNAPSHOT 427
15.16.2 REVENUE ANALYSIS 427
15.16.3 PRODUCT PORTFOLIO 428
15.16.4 RECENT DEVELOPMENT 428
15.17 SWEDISH ORPHAN BIOVITRUM AB (PUBL) 429
15.17.1 COMPANY SNAPSHOT 429
15.17.2 REVENUE ANALYSIS 429
15.17.3 PRODUCT PORTFOLIO 429
15.17.4 RECENT DEVELOPMENTS 430
15.18 TEVA PHARMACEUTICAL USA INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.) 431
15.18.1 COMPANY SNAPSHOT 431
15.18.2 REVENUE ANALYSIS 431
15.18.3 PRODUCT PORTFOLIO 432
15.18.4 RECENT DEVELOPMENTS 432
15.19 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA) 433
15.19.1 COMPANY SNAPSHOT 433
15.19.2 REVENUE ANALYSIS 433
15.19.3 PRODUCT PORTFOLIO 433
15.19.4 RECENT DEVELOPMENTS 434
16 QUESTIONNAIRE 435
17 RELATED REPORTS 438
List Of Figure
LIST OF FIGURES
FIGURE 1 GLOBAL BLAU SYNDROME MARKET: SEGMENTATION 64
FIGURE 2 GLOBAL BLAU SYNDROME MARKET : DATA TRIANGULATION 67
FIGURE 3 GLOBAL BLAU SYNDROME MARKET: DROC ANALYSIS 68
FIGURE 4 GLOBAL BLAU SYNDROME MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 69
FIGURE 5 GLOBAL BLAU SYNDROME MARKET: COMPANY RESEARCH ANALYSIS 69
FIGURE 6 GLOBAL BLAU SYNDROME MARKET: MULTIVARIATE MODELLING 70
FIGURE 7 GLOBAL BLAU SYNDROME MARKET: INTERVIEW DEMOGRAPHICS 71
FIGURE 8 GLOBAL BLAU SYNDROME MARKET: DBMR MARKET POSITION GRID 72
FIGURE 9 GLOBAL BLAU SYNDROME MARKET: VENDOR SHARE ANALYSIS 73
FIGURE 10 GLOBAL BLAU SYNDROME MARKET: SEGMENTATION 76
FIGURE 11 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL BLAU SYNDROME MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 77
FIGURE 12 HIGH ADOPTION OF BIOLOGICAL THERAPIES AND HIGH DEMAND OF DISEASE SPECIFIC TREATMENT IS DRIVING THE GLOBAL BLAU SYNDROME MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 78
FIGURE 13 TREATMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL BLAU SYNDROME MARKET IN 2020 & 2027 78
FIGURE 14 NORTH AMERICA IS THE FASTEST GROWING MARKET IN GLOBAL BLAU SYNDROME MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 79
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES OF GLOBAL BLAU SYNDROME MARKET 83
FIGURE 16 GLOBAL BLAU SYNDROME MARKET: BY TYPE, 2019 95
FIGURE 17 GLOBAL BLAU SYNDROME MARKET: BY TYPE, 2019-2027 (USD THOUSAND) 96
FIGURE 18 GLOBAL BLAU SYNDROME MARKET: BY TYPE, CAGR (2020-2027) 96
FIGURE 19 GLOBAL BLAU SYNDROME MARKET: BY TYPE, LIFELINE CURVE 97
FIGURE 20 GLOBAL BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, 2019 107
FIGURE 21 GLOBAL BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, 2019-2027 (USD THOUSAND) 108
FIGURE 22 GLOBAL BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, CAGR (2020-2027) 108
FIGURE 23 GLOBAL BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, LIFELINE CURVE 109
FIGURE 24 GLOBAL TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, 2019 114
FIGURE 25 GLOBAL TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD THOUSAND) 115
FIGURE 26 GLOBAL TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027) 115
FIGURE 27 GLOBAL TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 116
FIGURE 28 GLOBAL BLAU SYNDROME MARKET: BY END USER, 2019 123
FIGURE 29 GLOBAL BLAU SYNDROME MARKET: BY END USER, 2019-2027 (USD THOUSAND) 124
FIGURE 30 GLOBAL BLAU SYNDROME MARKET: BY END USER, CAGR (2020-2027) 124
FIGURE 31 GLOBAL BLAU SYNDROME MARKET: BY END USER, LIFELINE CURVE 125
FIGURE 32 GLOBAL BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2019 130
FIGURE 33 GLOBAL BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSAND) 131
FIGURE 34 GLOBAL BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027) 131
FIGURE 35 GLOBAL BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 132
FIGURE 36 GLOBAL BLAU SYNDROME MARKET: SNAPSHOT (2019) 139
FIGURE 37 GLOBAL BLAU SYNDROME MARKET: BY REGION (2019) 140
FIGURE 38 GLOBAL BLAU SYNDROME MARKET: BY REGION (2020 & 2027) 140
FIGURE 39 GLOBAL BLAU SYNDROME MARKET: BY REGION (2019 & 2027) 141
FIGURE 40 GLOBAL BLAU SYNDROME MARKET: BY TYPE (2020-2027) 141
FIGURE 41 NORTH AMERICA BLAU SYNDROME MARKET: SNAPSHOT (2019) 143
FIGURE 42 NORTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2019) 144
FIGURE 43 NORTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 144
FIGURE 44 NORTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 145
FIGURE 45 NORTH AMERICA BLAU SYNDROME MARKET: BY TYPE (2020-2027) 145
FIGURE 46 EUROPE BLAU SYNDROME MARKET: SNAPSHOT (2019) 167
FIGURE 47 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2019) 168
FIGURE 48 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 168
FIGURE 49 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 169
FIGURE 50 EUROPE BLAU SYNDROME MARKET: BY TYPE (2020-2027) 169
FIGURE 51 ASIA PACIFIC BLAU SYNDROME MARKET: SNAPSHOT (2019) 254
FIGURE 52 ASIA PACIFIC BLAU SYNDROME MARKET: BY COUNTRY (2019) 255
FIGURE 53 ASIA PACIFIC BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 255
FIGURE 54 ASIA PACIFIC BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 256
FIGURE 55 ASIA PACIFIC BLAU SYNDROME MARKET: BY TYPE (2020-2027) 256
FIGURE 56 SOUTH AMERICA BLAU SYNDROME MARKET: SNAPSHOT (2019) 324
FIGURE 57 SOUTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2019) 325
FIGURE 58 SOUTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 325
FIGURE 59 SOUTH AMERICA BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 326
FIGURE 60 SOUTH AMERICA BLAU SYNDROME MARKET: BY TYPE (2020-2027) 326
FIGURE 61 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: SNAPSHOT (2019) 350
FIGURE 62 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: BY COUNTRY (2019) 351
FIGURE 63 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027) 351
FIGURE 64 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027) 352
FIGURE 65 MIDDLE EAST & AFRICA BLAU SYNDROME MARKET: BY TYPE (2020-2027) 352
FIGURE 66 GLOBAL BLAU SYNDROME MARKET: COMPANY SHARE 2019 (%) 392
FIGURE 67 NORTH AMERICA BLAU SYNDROME MARKET: COMPANY SHARE 2019 (%) 393
FIGURE 68 EUROPE BLAU SYNDROME MARKET: COMPANY SHARE 2019 (%) 394
FIGURE 69 ASIA-PACIFIC BLAU SYNDROME MARKET: COMPANY SHARE 2019 (%) 395
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Companies
Novartis AG
Pfizer Inc.
AbbVie Inc.
Amgen Inc.
Janssen Pharmaceuticals, Inc.(A Subsidiary of Johnson & Johnson Services Inc.)
Mylan N.V.
Hikma Pharmaceuticals PLC
Teva Pharmaceutical U.S.A Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.)
Fulgent Genetics Inc.
Invitae Corporation
Swedish Orphan Biovitrum AB
Alkem Labs
Accord Healthcare
F. Hoffmann-La Roche Ltd
Zydus Pharmaceuticals (USA) Inc. (a subsidiary of Zydus cadila)
Amneal Pharmaceuticals LLC
Salix Pharmaceuticals (a subsidiary of Bausch Health Companies Inc.)
Centogene AG
Oncodesign
: +91 9015378249
Related Reports
Page 157 | 
June 2021
Page 130 | December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020